Last reviewed · How we verify
Aflibercept (Eylea)
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their pro-angiogenic signaling.
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their pro-angiogenic signaling. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Aflibercept (Eylea) |
|---|---|
| Also known as | Eylea (anti-VEGF agent), EYLEA |
| Sponsor | Ahmad Zeeshan Jamil |
| Drug class | VEGF inhibitor / Soluble decoy receptor |
| Target | VEGF-A, VEGF-B, PlGF (Placental Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their endothelial cell receptors, thereby suppressing pathological neovascularization and vascular permeability. This mechanism is particularly effective in ocular conditions where abnormal blood vessel growth drives vision loss.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (PHASE1)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
- A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (PHASE3)
- Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (PHASE3)
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (PHASE3)
- An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aflibercept (Eylea) CI brief — competitive landscape report
- Aflibercept (Eylea) updates RSS · CI watch RSS
- Ahmad Zeeshan Jamil portfolio CI